Background/Objectives: Multi-target claims in computational studies of Alzheimer’s disease rest on docking scores compared across receptors, although receptor-specific baselines are rarely established. We asked whether such concordance reflects binding-site complementarity or the calculation. Methods: 264 flavonoids were filtered by predicted absorption, distribution, metabolism, excretion and toxicity (ADMET) and prioritized by predicted kinase activity (49 retained); network pharmacology identified eight Alzheimer-associated core targets. Glide extra-precision (XP) docking was validated at each receptor by re-docking the co-crystallized ligand, whose score served as a receptor-specific baseline. ATP pockets were compared structurally, and the analysis was repeated for 122 unrelated compounds. Results: Baselines spanned −2.515 to −10.920 kcal/mol, exceeding the differences between compounds; normalization reordered the campaign completely (Spearman ρ = 0.078). Scores correlated between all kinase pairs (mean r = 0.693) yet showed no detectable relationship with pocket sequence identity (Mantel p = 0.29) or any SiteMap descriptor, whereas free hydroxyl count—the dominant marker of a polarity axis—explained 50–80% of the variance, its removal collapsing the correlation to 0.080. The diverse library reproduced stronger agreement (mean r = 0.776) on one latent axis carrying 81.4% of the variance, again showing no relationship to pocket similarity (p = 0.86). Robinetin ranked first at AKT1 after normalization and stayed in the ATP cleft throughout two independent 100 ns trajectories (Molecular Mechanics/Generalized Born Surface Area, MM-GBSA, −137.2 ± 20.7 kcal/mol), although hydrogen-bond occupancies differed between runs. Conclusions: Concordant docking scores reflect the calculation rather than binding-site complementarity and cannot alone support a multi-target mechanism; receptor normalization and ligand-descriptor deconvolution are minimum requirements.
Background Molecular hybridization in drug design is proved to be very successful approach to provide new chemical entities with potential activities and desirable physicochemical properties. Histone deacetylases (HDACs) are involved in controlling the behavior and acetylation of histone and non-histone proteins and their inhibition causes block of cell growth, differentiation, changes in gene expression, and death. Consequently, HDAC inhibitors may lead to anticytotoxic activity. An approach of synthesizing hybrid molecules of benzothiazole cross-linked with hydroxamic acid via an amino acid or aminoalkanoic acid was considered. This approach is expected to optimize the anticytotoxic activity of the proposed compounds. Methods Hybrid molecules of benzothiazole cross-linked with hydroxamic acid (2A-E) were synthesized and their chemical structures were confirmed by spectral analyses (FT-IR, 1H-NMR and 13C-NMR). These were subjected to molecular docking on HDAC8 (PDB ID: 1T69). Computational methods were employed using the SwissADME server to predict the ADME parameters and other physicochemical properties. The cytotoxicity evaluation was performed using MTT colorimetric assay. Results Hybrids (2A-E) recorded lower ΔG (-6.322 to - 9.46) than Vorinostat (SAHA, -5.375). ΔG is an affinity scoring function (kcal/mol) and is employed to rank the candidate poses as the sum of the electrostatic and Van der Waals energies. Benzothiazole cross-linked with hydroxamic acid by a p-aminobenzoic acid (2E) has recorded the lowest docking score of -9.460 and this may refer to the possibility of high inhibitory activity. The hybrids showed no violation from Lipinski’s rule and complied with parameters with low possible passive oral absorption and no penetration into BBB. Hybrid molecules of benzothiazole recorded very interesting results, particularly, 2D and 2E which showed significant and remarkable activity. Conclusions Hybrid molecules of benzothiazole cross-linked with hydroxamic acid recorded very interesting results, particularly, compounds 2D and 2E which showed significant and remarkable activity on lung cancer cell line type A549.